Du är här

2016-05-12

Medical Prognosis Institute: MPI - Positive data on MPI's DRP for 5-FU published in PLOS ONE

Hoersholm, Denmark; May 12th, 2016 - Medical Prognosis Institute A/S announces
that positive data on their Drug Response Predictor (DRP), has been published
in the journal PLOS ONE with the title: "Cell line derived 5-FU and
irinotecan drug-sensitivity profiles evaluated in adjuvant colon cancer trial
data." Data from a prospective randomized clinical trial was analyzed with
the unique DRP tool. The DRP(TM) for 5-FU could identify which patients
benefitted from treatment with 5-FU. When looking at overall survival the
patients with the most positive predictor have twice the survival rate of the
patients with poor prediction.
"The publication in PLOS ONE is an another important mile stone documenting
the solid data on the Drug Response Predictor - DRP(TM) - both demonstrated
in prospective, retrospective and blinded clinical studies - this time in
collaboration with an international well known academic group. All
calculations were done by external researchers that are independent from MPI"
said Adjunct professor Peter Buhl Jensen, M.D., DMSc and CEO of Medical
Prognosis Institute.

"5-FU is one of the most important chemotherapeutics which is widely used
around the world - and yet there is until now no biomarker in clinic to tell
whether a patient is likely to benefit from the treatment or not. I believe
that the specific 5-FU DRP(TM) has potential to increase the survival rate of
cancer patients
" Peter Buhl Jensen further added
.

In this international collaboration between MPI and two independent public
science groups gene expression from tumors from 636 stage III colon cancer
patients was evaluated. Conclusion was that "The 5-FU predictor was
prognostic in stage III patients in PETACC-3 but not in stage II patients
with no adjuvant therapy. This suggests a potential predictive ability of the
5-FU sensitivity profile to identify colon cancer patients who may benefit
from 5-FU."

Selected data from the publication shows that the 5-FU specific DRP(TM) in
PETACC-3 showed a statistically significant association with relapse free
survival (RFS) (hazard ratio (HR) = 0.54 (0.41-0.71), p<1e-05) and overall
survival (HR = 0.47 (0.34-0.63), p<1e-06). The effect of the 5-FU profile
remained significant in a multivariable model, adjusting for several relevant
clinical and tissue specific parameters.

Please find the full publication on:
PLOS ONE

About MPI

Medical Prognosis is a publicly traded international company specialized in
improving cancer patients lives by developing Personalized Medicine using its
unique DRP(TM) technology. MPI's exceptional opportunity to personalize
cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma
and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its
ability to separate patients who benefit and who do not benefit from a
specific cancer treatment. This has been shown in as many as 29 out of 37
trials, and covers more than 80 anti-cancer treatments in a wide range of
cancer indications. MPI has built a significant large database with over
1,000 screened breast cancer patients and is building up a database in
Multiple Myeloma to be followed by Prostate cancer in collaboration with
oncologists and hematologists throughout Denmark.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)

MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to
predict which cancer patients are high likely to respond to a given
anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29
trials showed that drug-specific DRP(TM) Biomarkers could predict which
patients responded well to the treatment. The DRP(TM) platform has amongst
others been externally validated and published in collaboration with leading
statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be
used to design the Clinical Development Plan, i.e. to select which
indications are relevant for a given anti-cancer drug. In addition to
this, the individual genetic patterns of patients can be analyzed as part of
a screening procedure for a clinical trial to ensure inclusion of patients
with a high likelihood of response to the drug. DRP(TM) builds on comparison
between sensitive and resistant human cancer cell lines, including genomic
information from cell lines combined with clinical tumor biology and clinical
correlates in a systems biology network. MicroRNA is used on certain products
whereas the messengerRNA is more broadly useable and more validated. The
DRP(TM) platform can be used in all cancer types, and has been patented for
more than 60 anti-cancer drugs in the US.

For further information, please contact

CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.d.
E-mail: pbj@medical-prognosis.com
Phone: +45 21 60 89 2

Certified Advisor:
Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup,
Denmark

MPI - Positive data on MPI's DRP for 5-FU published in PLOS ONE
http://hugin.info/158657/R/2012368/745394.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medical Prognosis Institute via Globenewswire

HUG#2012368

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.